Sativex is a way to improve symptoms of spasticity for people with MS1

Now officially recommended after first health technology appraisal2 Click here for more information

References

1. Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131.

2. AWMSG, 2014. Sativex Preliminary Appraisal Recommendation. Available from: http://www.awmsg.org/awmsgonline/app/appraisalinfo/644.
Accessed August 2014.


This website is intended for healthcare professionals resident in the UK. Date of update May 2016
L.GB.MKT.03.2016.15190
For UK Healthcare Professional. Report adverse events. Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc. Tel: 01635 563500, Fax: 01635 563703, Email: pvuk@bayer.com